FreeOx has developed the first cerebroprotective therapy designed to preserve the brain during acute ischemic stroke. It is the key piece in stroke treatment, as it focuses on microcirculation and solves the problem of reperfusion. Its annual market potential exceeds $3 billion.
- The crowdfunding round amounts to €2.5 million.
- Every 3 seconds, someone in the world suffers a stroke.
- Each year, 13 million people are affected.
- 50% of survivors are left with disabilities.
FreeOx Biotech, the spin-off from Hospital Clínic de Barcelona co-founded by Dr. Ángel Chamorro, is launching a crowdfunding campaign to support the start of its Phase IIb/III clinical trial scheduled for 2026 in the United States, with the support of NINDS, the division specialized in neurodegenerative diseases and stroke at the prestigious National Institutes of Health (NIH).
This €2.5 million funding round will allow the company to advance the clinical development of its innovative cerebroprotective drug Ox-01, aimed at patients who have suffered an ischemic stroke and have been treated with mechanical thrombectomy.
The project, led by renowned neurologist Ángel Chamorro, is based on a patented formulation of an endogenous compound administered intravenously, which protects the brain — particularly the microcirculation — during the onset of stroke, which remains the leading cause of acquired disability worldwide. Ox-01 represents one of the few advanced-stage cerebroprotective therapies with positive clinical results. In the last 30 years, no new treatment for ischemic stroke has been launched on the market.
The company has attracted the interest of NINDS, the neurology institute of the NIH (National Institutes of Health, USA), which has committed to funding a clinical trial in 38 U.S. hospitals. This Phase IIb/III clinical trial will include more than 800 patients. This support represents an exceptional recognition for a European biotech company and has also been key in attracting private investors such as NTI (Neurotechnology Investors), the lead investor in this funding round.
FreeOx is now seeking to expand its investor base through Capital Cell, Europe’s leading investment platform in biotechnology and healthcare, addressing individual investors who are sensitive to the social impact of its technology.
According to Dr. Chamorro: “Ox-01 is the result of more than twenty years of clinical research and represents a real opportunity to prevent stroke-related sequelae in thousands of patients each year. The support of U.S. health authorities confirms its transformative potential.”
The public campaign opens today and is available to any individual investor starting from €3,000 at https://capitalcell.com/campaign/freeox/
FreeOx Biotech en vídeo: https://www.youtube.com/watch?v=-gjZktmAfMI
